The contents of this publication are solely the responsibility of the authors and do not necessarily reflect the views of the Canine Health Foundation.
Double-Masked, Placebo-Controlled Study of Intravenous Levetiracetam for the Treatment of Status Epilepticus and Acute Repetitive Seizures in Dogs
Article first published online: 1 FEB 2012
Copyright © 2012 by the American College of Veterinary Internal Medicine
Journal of Veterinary Internal Medicine
Volume 26, Issue 2, pages 334–340, March-April 2012
How to Cite
Hardy, B.T., Patterson, E. E., Cloyd, J.M., Hardy, R.M. and Leppik, I.E. (2012), Double-Masked, Placebo-Controlled Study of Intravenous Levetiracetam for the Treatment of Status Epilepticus and Acute Repetitive Seizures in Dogs. Journal of Veterinary Internal Medicine, 26: 334–340. doi: 10.1111/j.1939-1676.2011.00868.x
- Issue published online: 20 MAR 2012
- Article first published online: 1 FEB 2012
- Manuscript Accepted: 1 DEC 2011
- Manuscript Revised: 3 NOV 2011
- Manuscript Received: 2 AUG 2011
- American Kennel Club Canine Health Foundation
- Cluster seizures;
Status epilepticus (SE) and acute repetitive seizures (ARS) are common canine neurologic emergencies. No evidence-based studies are available to guide treatment in veterinary patients. Parenteral levetiracetam (LEV) has many favorable properties for the emergency treatment of seizures, but its safety and efficacy in dogs for SE and ARS are unknown.
Intravenous LEV is superior to placebo in controlling seizures in dogs with SE or ARS after treatment with IV diazepam.
Nineteen client-owned dogs admitted for SE or ARS.
Randomized, placebo-controlled, double-masked study. Dogs with SE or ARS were randomized to receive IV LEV (30 or 60 mg/kg using an adaptive dose-escalation approach) or placebo, in addition to standard of care treatment. They were monitored for at least 24 hours after admission for additional seizures.
The responder rate (defined as dogs with no additional seizures after administration of the study medication) after LEV was 56% compared with 10% for placebo (P = .06). Dogs in the placebo group required significantly more boluses of diazepam compared with the LEV group (P < .03). Seizure etiologies identified were idiopathic epilepsy (n = 10), inflammatory central nervous system disease (n = 4), intracranial neoplasia (n = 2), hepatic encephalopathy (n = 1), and 2 dogs had no cause determined. No serious adverse effects were attributable to LEV administration.
Conclusions and Clinical Importance
LEV was safe and potentially effective for the treatment of SE and ARS in these client-owned dogs. Larger, controlled clinical trials are needed to confirm this preliminary observation.